741
Citations
199
Journals
2006
First Cited
2022
Last Cited

Articles citing This Document (Page 3 of 15)

ArticleJournalYear
Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial2022
Advanced age portends poorer prognosis after radical prostatectomy: a single center experience
Factors influencing survival in metastatic castration resistant prostate cancer therapy
Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
Immediate Versus Salvage Postoperative Radiotherapy in High-Risk Prostate Cancer Patients: A Critical Review2022
Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer2022
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer2022
Systemic Treatments and Related Side Effects in Prostate Cancer2022
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancerScientific Reports2022
The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group)Medicina (Lithuania)2022
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborativeUrologic Oncology: Seminars and Original Investigations2022
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancerProstate Cancer and Prostatic Diseases
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trialActa Oncológica
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and TrendsClinical Drug Investigation
Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate CancerCancers2022
Prostate specif c antigen density as a prognostic factor in patients with prostate cancer treated with combined hormonal radiation therapySiberian Journal of Oncology2022
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancerProstate
More Unacceptable Denials: Now It’s PSMA-Targeted PET/CT ImagingJournal of Nuclear Medicine2022
PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary MalignanciesCancers2022
The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort StudyJournal of Clinical Medicine2022
Comparison of Estimated Late Toxicities between IMPT and IMRT Based on Multivariable NTCP Models for High-Risk Prostate Cancers Treated with Pelvic Nodal RadiationInternational Journal of Particle Therapy2022
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked datasetUrologic Oncology: Seminars and Original Investigations2022
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case reportBMC Medical Genomics2022
Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10Cancers2022
Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and managementEuropean Journal of Nuclear Medicine and Molecular Imaging
Clinical implications of homologous recombination repair mutations in prostate cancerProstate2022
Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapyBrachytherapy2022
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer Expert Review of Anticancer Therapy
Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017Cancer Medicine
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.Current Oncology Reports2022
Recent results of HDR brachytherapy in the treatment of localized forms of prostate cancerUkrainian Journal of Radiology and Oncology2022
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular Diagnosis and Therapy2022
Evolving trends in the management of low-risk prostate cancerClinical Genitourinary Cancer2022
Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study.Frontiers in Medicine2022
Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study.Radiation Oncology2022
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.BMC Cancer2022
Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancerOnkologiya Zhurnal Imeni P A Gertsena2022
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.Journal of Medical Economics2022
Table_1.docx2020
Data_Sheet_1.ZIP2020
DataSheet_1.docx2020
Table_1.DOCX2020
"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer" (MENHYP-ENI).International Journal of Radiation Oncology Biology Physics2022
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomyProstate2021
Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study.Prostate Cancer and Prostatic Diseases2021
Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal BalloonsInternational Journal of Particle Therapy2022
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.Research and Reports in Urology2022
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate AdenocarcinomaAdvances in Radiation Oncology2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer.Frontiers in Oncology2022
Prediction of surgical margin status and location after radical prostatectomy using positive biopsy sites on 12-core standard prostate biopsy.Scientific Reports2022
Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy.Radiologia Medica2022
Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.Advances in Therapy2022
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker.Cancers2022
Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.European Radiology2022
Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel.Frontiers in Oncology2022
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.Prostate Cancer and Prostatic Diseases2022
Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.Journal of Racial and Ethnic Health Disparities2022
Urban-rural prostate cancer disparities in a regional state of Australia.Scientific Reports2022
Germline alterations among Hispanic men with prostate cancer.Prostate Cancer and Prostatic Diseases2022
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.Journal of Personalized Medicine2021
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Network Open2021
Prognostic significance of PTEN, RB1 and BRCA2 gene loss in patients with localized and locally advanced prostate cancerOnkourologiya2022
Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT.Clinical Genitourinary Cancer2022
Combinatorial radiation therapy for prostate cancer with seminal vesicle invasionOnkourologiya2022
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.European Urology2021
Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.Brachytherapy2022
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis.Frontiers in Pharmacology2021
Prostate Health Index () and its derivatives predict Gleason score upgrading after radical prostatectomy among patients with low-risk prostate cancerAsian Journal of Andrology2021
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study.Frontiers in Oncology2021
Approach to the Treatment of Metastatic Castration-Sensitive Prostate Carcinoma: A Single Center ExperienceJournal of Basic and Clinical Health Sciences
Genitourinary System Cancers2022
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.Prostate Cancer and Prostatic Diseases2022
Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer.Journal of Personalized Medicine2022
Practice-level variation in the decision to biopsy PI-RADS 3 lesions in favorable-risk prostate cancer patients.Urology2022
PROFOUND trial -a new era in targeted therapeutics for prostate carcinoma.Indian Journal of Urology2022
Testosterone levels and testosterone kinetics: The importance of its clinical significance.Radiotherapy and Oncology2022
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.Journal of Personalized Medicine2022
Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.World Journal of Men?s Health2022
Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer.Clinical Genitourinary Cancer2021
Osteoporosis: Common Side EffectClinical Journal of Oncology Nursing2021
Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of OpportunityJournal of Personalized Medicine2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)International Journal of Molecular Sciences2021
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trialSupportive Care in Cancer2021
Application of Machine Learning Techniques to Predict Bone Metastasis in Patients with Prostate CancerCancer Management and Research2021
Biomarkers for Treatment Response in Advanced Prostate CancerCancers2021
Comparison of Clinical Outcomes of Radical Prostatectomy versus IMRT with Long-Term Hormone Therapy for Relatively Young Patients with High- to Very High-Risk Localized Prostate CancerCancers2021
The Impact of 18F-DCFPyL PSMA PET-CT in the Management of Prostate Cancer Biochemical RecurrenceOpen Journal of Urology2021
Perceptions of partial gland ablation for prostate cancer among men on active surveillance: A qualitative study
The utility of a deep learning-based algorithm for bone scintigraphy in patient with prostate cancerAnnals of Nuclear Medicine2020
Chemotherapy and Prostate Cancer2021
Androgen Deprivation Therapy2021
Medical Oncology2008
Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity.Value in Health2022
Prostate Cancer2020
Comparative evaluation of results of high and low dose rate brachytherapy in treatment of localized prostate cancerOnkologiya Zhurnal Imeni P A Gertsena2020
Chemotherapeutic Agents for Urologic Oncology: Basic Principles2020
The Value of Incorporating Multiparametric MRI for Active Surveillance in Patients with Prostate Cancer2020
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohortPLoS ONE2020
Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate CancerFrontiers in Oncology2020
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future TrendsCancers2021
Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institutionBrachytherapy2021
Radiotherapy for Prostate Cancer2021
Validity of using cancer registry data for comparative effectiveness research
Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancerRevista Espanola De Medicina Nuclear E Imagen Molecular2019
Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk
Androgen Deprivation Therapy for Advanced Prostate Cancer2019
Prostate Cancer2019
Androgen Deprivation Therapy for Advanced Prostate Cancer2019
SBRT for High-Risk Prostate Cancer2019
How We Led the Japanese Low-Dose-Rate Brachytherapy to Successful Practice (Urologist Perspective)2019
Risk Assessment Among Patients Receiving Primary ADT for Prostate Cancer2018
[8. How We Can Treat the Patients with Prostate Cancer-Surgical Option and Change over Time]Japanese Journal of Radiological Technology2018
Side Effects of Medical Cancer Therapy in Genitourinary Malignancies2018
Prostate Gland Pathology2018
Evaluation and Treatment for High-Risk Prostate Cancer2018
ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY AND PROGNOSTIC STRATIFICATION IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCEREUREKA Health Sciences2017
Komorbidität in der geriatrische Urologie2016
Genitourinary Sites2016
Prostate Cancer2015
Komorbidität in der geriatrische Urologie2015
Pelvic Lymphadenectomy for Prostate and Bladder Cancer2015
New Imaging ModalitiesCurrent Clinical Urology2014
[Comparison of ventral and dorsal lymph node metastases of obturator nerve in radical prostatectomy]Japanese Journal of Urology2014
Prostate Carcinoma Surveillance Counterpoint: USA2013
Genitourinary Cancer2013
Decision Making in Elderly Localized Prostate Cancer2013
Clinical Management of Elderly Patients’ Metastatic Prostate Cancer: Other Treatments and Supportive Care2013
The Role for Radical Prostatectomy in Advanced Prostate Cancer2012
Cancer de la prostate2011
Prostate Cancer2010
Prostate Cancer Stem/Progenitor Cells2009
Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer?Academic Radiology2021
Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancerJournal of Medical Radiation Sciences2021
Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate CancerCancers2021
Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancerWorld Journal of Nuclear Medicine2018
Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical ProstatectomyWorld Journal of Nuclear Medicine2017
Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancerRadiation Oncology Journal2015
Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using a Couple-Focused mHealth Symptom Self-Management Program: Protocol for a Feasibility StudyJMIR Research Protocols2018
Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patientsPLoS ONE2018
Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO)PLoS ONE2017
On Risk Estimation versus Risk Stratification in Early Prostate CancerPLoS Medicine2016
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patientsProstate Cancer and Prostatic Diseases2021
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology2020
Magnetic resonance as imaging diagnostic tool in prostate cancer: New evidences-The EAU Section of Uro-Technology positionActas Urológicas Españolas2020
Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparisonActas Urológicas Españolas2019
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate CancerDrugs2021
High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer2019
Management of Localized and Locally Advanced Prostate Cancer2020